Laird Norton Wetherby Wealth Management’s GSK GSK Stock Holding History

Laird Norton Wetherby Wealth Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$1.1M	Sell	25,507 -1,553	-6%	-$60.7K	0.04%	357
2025 Q2	$1.04M	Buy	+27,060	New	+$1.03M	0.05%	356
2024 Q4	$894K	Sell	26,447 -11,992	-31%	-$432K	0.04%	361
2024 Q3	$1.57M	Sell	38,439 -9,372	-20%	-$383K	0.07%	263
2024 Q2	$1.84M	Sell	47,811 -6,081	-11%	-$256K	0.09%	219
2024 Q1	$2.31M	Buy	53,892 +2,344	+5%	+$96.7K	0.11%	195
2023 Q4	$1.91M	Buy	51,548 +3,927	+8%	+$141K	0.1%	219
2023 Q3	$1.73M	Buy	47,621 +2,328	+5%	+$82.6K	0.1%	219
2023 Q2	$1.61M	Buy	45,293 +5,418	+14%	+$194K	0.09%	244
2023 Q1	$1.42M	Buy	39,875 +3,648	+10%	+$128K	0.08%	257
2022 Q4	$1.27M	Buy	36,227 +16,397	+83%	+$546K	0.08%	272
2022 Q3	$584K	Sell	19,830 -5,899	-23%	-$224K	0.04%	440
2022 Q2	$1.4M	Sell	25,729 -1,364	-5%	-$75.3K	0.1%	220
2022 Q1	$1.48M	Buy	27,093 +112	+0.4%	+$6.08K	0.08%	226
2021 Q4	$1.49M	Buy	26,981 +3,973	+17%	+$207K	0.08%	223
2021 Q3	$1.1M	Buy	23,008 +4,128	+22%	+$207K	0.07%	274
2021 Q2	$939K	Buy	18,880 +1,444	+8%	+$69.4K	0.06%	321
2021 Q1	$778K	Sell	17,436 -1,969	-10%	-$89.4K	0.06%	319
2020 Q4	$893K	Sell	19,405 -9,025	-32%	-$415K	0.06%	298
2020 Q3	$1.34M	Sell	28,430 -3,464	-11%	-$174K	0.12%	164
2020 Q2	$1.63M	Buy	31,894 +6,377	+25%	+$327K	0.15%	126
2020 Q1	$1.21M	Sell	25,517 -8,802	-26%	-$470K	0.14%	150
2019 Q4	$2.02M	Sell	34,319 -1,162	-3%	-$64.6K	0.2%	113
2019 Q3	$1.89M	Buy	35,481 +3,008	+9%	+$155K	0.2%	118
2019 Q2	$1.62M	Buy	32,473 +1,306	+4%	+$65.5K	0.18%	133
2019 Q1	$1.63M	Buy	31,167 +5,068	+19%	+$253K	0.2%	112
2018 Q4	$1.25M	Sell	26,099 -3,461	-12%	-$170K	0.18%	126
2018 Q3	$1.48M	Buy	29,560 +1,758	+6%	+$89.3K	0.18%	121
2018 Q2	$1.4M	Buy	27,802 +5,884	+27%	+$296K	0.19%	114
2018 Q1	$1.07M	Buy	21,918 +8,299	+61%	+$386K	0.15%	164
2017 Q4	$604K	Sell	13,619 -7,135	-34%	-$330K	0.08%	301
2017 Q3	$1.05M	Buy	20,754 +80	+0.4%	+$4.06K	0.16%	150
2017 Q2	$1.11M	Buy	20,674 +1,205	+6%	+$64.2K	0.19%	123
2017 Q1	$1.03M	Buy	19,469 +6,781	+53%	+$344K	0.18%	122
2016 Q4	$611K	Sell	12,688 -8,214	-39%	-$406K	0.12%	221
2016 Q3	$1.13M	Buy	20,902 +744	+4%	+$40.8K	0.23%	97
2016 Q2	$1.09M	Sell	20,158 -95	-0.5%	-$5K	0.24%	88
2016 Q1	$1.03M	Buy	20,253 +1,118	+6%	+$55.7K	0.24%	89
2015 Q4	$965K	Buy	19,135 +2,281	+14%	+$116K	0.23%	95
2015 Q3	$810K	Buy	16,854 +3,137	+23%	+$163K	0.21%	105
2015 Q2	$714K	Sell	13,717 -2,537	-16%	-$143K	0.17%	133
2015 Q1	$938K	Buy	16,254 +2,956	+22%	+$169K	0.23%	93
2014 Q4	$710K	Sell	13,298 -1,006	-7%	-$56.3K	0.18%	120
2014 Q3	$822K	Sell	14,304 -774	-5%	-$47.5K	0.23%	100
2014 Q2	$1.01M	Buy	15,078 +431	+3%	+$29.2K	0.28%	77
2014 Q1	$978K	Buy	14,647 +533	+4%	+$36K	0.28%	80
2013 Q4	$942K	Buy	14,114 +86	+0.6%	+$5.58K	0.27%	85
2013 Q3	$879K	Buy	14,028 +890	+7%	+$57.3K	0.27%	83
2013 Q2	$820K	Buy	+13,138	New	+$834K	0.29%	80

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Laird Norton Wetherby Wealth Management's GSK Position: Q3 2025 in Review

Laird Norton Wetherby Wealth Management reduced its GSK (GSK) stake by 5.7% in Q3 2025, selling an estimated $60.7K and leaving 25,507 shares worth $1.1M. The position accounts for 0.04% of the portfolio, ranked #357.

Laird Norton Wetherby Wealth Management first reported a position in GSK in Q2 2013 and has held it in 49 quarters since. The position peaked at $2.31M in Q1 2024. 895 funds tracked by Wall St. Rank hold GSK as of Q3 2025.

Laird Norton Wetherby Wealth Management held 25,507 shares of GSK worth $1.1M as of Q3 2025.
Laird Norton Wetherby Wealth Management sold 1,553 GSK shares in Q3 2025, an estimated $60.7K.
GSK made up 0.04% of Laird Norton Wetherby Wealth Management's portfolio in Q3 2025, its #357 holding.
Laird Norton Wetherby Wealth Management first reported a position in GSK in Q2 2013 and has held it in 49 quarters since.
Laird Norton Wetherby Wealth Management's GSK position peaked at $2.31M in Q1 2024.
895 funds tracked by Wall St. Rank held GSK as of Q3 2025.

Based on Laird Norton Wetherby Wealth Management's 13F filing for Q3 2025, filed 14 Nov 2025.